TrialBJU international2018

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.

Andrea Necchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.